SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalMcKesson HBOC (MCK)


Previous 10 Next 10 
To: Mort who wrote (150)2/1/2000 8:29:00 AM
From: Wally Mastroly
   of 165
 
Some MCK headlines this morning (Edit adds the article):

07:52 [MCK] MCKESSON HBOC SAYS ARROW CONTRACT WORTH $1 BILLION IN REVENUE

07:52 [MCK] MCKESSON HBOC EXTENDS PHARMACEUTICAL SUPPLY AGREEMENT WITH ARROW

biz.yahoo.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Wally Mastroly who wrote (151)2/22/2000 10:40:00 AM
From: Mort
   of 165
 
Somebody has faith in MCK

February 16, 2000 07:02 PM
WASHINGTON, Feb 16 (Reuters) - David Geffen, one of the three leaders at Hollywood film studio DreamWorks, said on Wednesday he acquired a stake currently worth more than $278 million in McKesson HBOC Inc.MCK , the largest U.S. drug distributor.

Geffen, who heads DreamWorks with Hollywood heavyweights Steven Spielberg and Jeffrey Katzenberg, acquired 5 percent, or 14,087,700 common shares, for general investment purposes, according to a filing with the U.S. Securities and Exchange Commission.

Using his personal funds, Geffen bought shares of San Francisco-based McKesson between Dec. 13 and Feb. 11 at prices ranging from $18.8750-$22.6250 a share.

The largest one-day purchase during that period were 1 million shares on Jan. 25 for $22.50 each, and an additional 1 million shares bought two days later at $20.9375 each.

Geffen disclosed his stake in the company because of SEC rules that say anyone holding a stake of 5 percent or more in a company must publicly report their holdings.


Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Mort who wrote (152)3/28/2000 10:51:00 PM
From: epicure
   of 165
 
up on 4x volume and nobody comments? WOW- did everyone sell? Am I all alone?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: epicure who wrote (153)3/28/2000 11:43:00 PM
From: dogemup
   of 165
 
Long MCK-I'm here.
I noticed the move and the volume. I'm long MCK since the big drop. Been buying in the 20's and high teens. I'm under water over 20% in one account, and up about 5% in another account. Don't have any good insight about the recent action. I think this is a value play and money is rotating into these kinds of stocks. Hoping the uptrend will continue.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: dogemup who wrote (154)3/28/2000 11:59:00 PM
From: epicure
   of 165
 
Nice to know you are out there. I was lonely.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: epicure who wrote (155)4/19/2000 12:44:00 AM
From: Phil Placier
   of 165
 
Any thoughts regarding when, if ever, this stock will increase about the 20 +/- level?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Phil Placier who wrote (156)4/19/2000 9:34:00 AM
From: epicure
   of 165
 
LEt me get out my psychic hat.....

From the chart, I'd guess soon. But I've been thinking that for a while, and I've been wrong.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: epicure who wrote (157)9/26/2000 10:31:31 AM
From: Kat
   of 165
 
Looks like we are all finally right on this one. I predict a run toward 50. Getting alot of attention !

Kat

Share RecommendKeepReplyMark as Last Read


To: Rob Pierce who started this subject1/11/2001 8:14:12 AM
From: Paul Lee
   of 165
 
TWST: Could you give our readers an overview of
iMcKesson (NYSE:MCK)?

Mr. Mahoney: iMcKesson is a six-month-old subsidiary
of McKesson HBOC Inc. that provides a combination of
both Web and legacy IT solutions for physician offices
and medical management tools a nd services for payors.
iMcKesson has leading positions in a number of market
segments within the payor and provider markets. We are
the leading provider of clinical appropriateness criteria.
We are the leader in decision support and clinical
resource management software. We are the leader in
outsourced phone-based care center telephone support
in medical management, and iMcKesson has the
industry’s second largest medical claims clearinghouse,
which processes more than 100 million medical claims
per year. Everything we do starts from a rigorous clinical
base with a focus on patient outcomes.

TWST: Do you have an international presence?

Mr. Mahoney: We have a large presence in the US with a presence in Canada,
the UK, Australia and New Zealand. So, for example, in Australia and New
Zealand, we provide medical management services for 8 million people.

TWST: What do you see as your most distinct competitive advantages?

Mr. Mahoney: A couple of things. First, and probably most important, is the
breadth of our offering. There are very few e-health companies that can address
as broad a range of needs that our customers have as well as we can. Second is
the broad scale of our customer base, and importantly, the scale of our installed
customers is unique. Third is our domain expertise. We are talented technologists
who really know health care. We are not trying to learn health care from a
technology base. We are bringing a very deep knowledge of health care to focus
on the problems our technology can solve today. Lastly, I would highlight that we
have a very strong clinical focus that comes from that healthcare expertise with
defensible intellectual property that backs up our products.

TWST: Will your strategy for growth also include mergers and
acquisitions?

Mr. Mahoney: Absolutely, because of the strength of our service and product
offering right now, we think that we will have a lot of opportunities to grow by
acquisition.

TWST: What do you see as the potential rate of gain in sales and earnings
for iMcKesson over the next year or so?

Mr. Mahoney: Our goals going forward, without putting a specific number around
them, are to maintain the leadership position that we have established in the core
medical management and claims processing markets. I think it is going to be very
important for us to make that leadership position more visible to both the customer
markets and to the capital markets. In addition, we will leverage the Internet to
expand upon our core triage medical management services capabilities, as well
as the opportunity created by HIPAA to increase the volume of medical claims
processed through our Transaction Solutions Hub. Additionally, we will be focused
on establishing PracticePoint Connect as the premier tool for Web-based
provider-patient communications.

CEO is concerned about the health of iMckesson's customer base
David Mahoney, iMcKesson
DAVID MAHONEY is the Chief Executive Officer of iMcKesson, business unit of McKesson HBOC, Inc.


For Subscribers
Get the complete article now!

TWST: Where will most of your potential revenue growth come from in the year?

Mr. Mahoney: About two-thirds of our current revenue comes from sales of our medical management solutions, and one-third from the physician office market. We are accelerating our growth in these segments, leveraging our re-focused, expanded medical management sales force and on the provider solutions side, our installed base in 20% of the nation’s largest physician practices. We anticipate the fastest growing pieces will be the services part of medical management and the claims clearinghouse part of the physician office solution.

TWST: What do you see as the most significant industry trends that will be taking place in the next year?

Mr. Mahoney: I think a couple of things. First, the increased need for health plans to focus on medical management effectiveness, responding to the trends of high premium rate increases, concerns by both employers and consumers about inappropriate utilization management, and the increasing empowerment of patients all leading, if you are a health plan, to be more focused on medical management effectiveness. The second key trend, and there has been a lot of emphasis on this, is the connectivity strategies between payors and providers, particularly physicians, but also hospitals and patients. This is being driven by regulatory changes, such as HIPAA, and by changes in the basic demographics of the US population, which is leading to more and more older people prone to chronic disease. Finally, of course, there is the trend of increasing utilization of the Web, both for delivering basic information to patients as well as to solve some of these medical management and connectivity issues.

TWST: What do you see as the most significant risks and challenges that iMcKesson (NYSE:MCK) will be facing?

Mr. Mahoney: The healthcare system as a whole is under pressure so that we are always concerned, and I think we need to be concerned going forward, about the health of our customer base. Whether you are talking about reimbursement pressures being put on our provider customer base or the regulatory and other pressures put on our health plan or payor customer base, that’s clearly something we worry about. Additionally, any business today needs to be quite concerned about a continued ability to attract and retain talent in a highly competitive market.

TWST: What are your thoughts and comments on the current stock prices for iMcKesson?

Mr. Mahoney: iMcKesson is a subsidiary of McKesson HBOC, which is traded on the NYSE under the symbol MCK.

Share RecommendKeepReplyMark as Last Read


To: Rob Pierce who started this subject1/23/2001 5:33:07 PM
From: Paul Lee
   of 165
 
McKesson: Co. 'Well-Positioned' On Generic
Drugs

Dow Jones Newswires

By Dinah Wisenberg Brin
Of DOW JONES NEWSWIRES

PHILADELPHIA -- McKesson HBOC Inc. (MCK), the country's largest
distributor of drugs and health-care products, posted fiscal third-quarter
results Tuesday that pleased Wall Street, despite missing analysts' consensus
estimate by a penny a share.

"We have a positive momentum building in our business," Chief Executive
John H. Hammergren said on a conference call with analysts.

The San Francisco company reported earnings from continuing operations,
excluding charges, of $69.3 million, or 24 cents a diluted share, compared
with earnings of $60.5 million, or 21 cents a share, in the same quarter the
previous year.

A First Call/Thomson Financial consensus of 18 analysts had estimated
earnings of 25 cents a share.

Analyst Leonard S. Yaffe of Banc of America Securities said he was pleased
with the results, which slightly exceeded his own estimate.

"Overall, it was a solid quarter and we saw nothing unusual relative to our
expectations," Yaffe said.

The stock had sold off in the past few weeks as investors worried McKesson
might miss analysts' estimates by a wide margin, he said.

"Now that the quarter came out and it was above our estimate, a penny
below consensus, I think people feel quite comfortable with the outlook of the
company, and we continue to rate the stock a buy," Yaffe said. He has a
12-month price target of $38 a share.

Analyst Ray Lewis of McDonald Investments Inc. liked the trends in
McKesson's two main businesses, supply management and information
technology.

"Both the revenue and margin trends in those businesses were slightly better
than what we had been looking for," Lewis said, though he noted that
McKesson's physician software unit, iMcKesson, posted a wider loss than
what he had expected.

Shares of McKesson were recently up $2.97, or 10.2%, at $31.97 a share
on the New York Stock Exchange on volume of 3.1 million shares. The
average daily volume is 1.7 million shares.

CEO Hammergren told analysts that McKesson should grow in the
low-to-middle double-digit range next year, which is in line with this quarter's
14% operating EPS growth. Profit margins should expand in the fourth
quarter and next fiscal year, but Hammergren wouldn't estimate by how much.

The company is "exceptionally well-positioned" to take advantage of the fact
that $48 billion worth of brand-name pharmaceuticals are coming off patent
and into the generic-drug realm over the next three years, Hammergren said,
citing its 7,000 independent-pharmacy customers.

In addition, Hammergren said that in the next several weeks, McKesson will
open its new comprehensive supply-management Web portal, which will
allow the company to expand its marketing opportunities to 7,000 customers
and reduce processing costs.

McKesson's supply-management and information-technology businesses are
building positive momentum, he said.

Revenue at the company's health-care IT unit, which supplies software and
networks to hospitals, fell 10.6% year-over-year to $199.8 million from
$223.6 million, but rose sequentially for the first time in six quarters. The IT
backlog also rose sequentially over the second quarter.

Operating profit at the health-care supply-management unit rose nearly 21%
before special items to $166.5 million from $137.9 million, while revenue rose
7.4% to $7 billion from $6.5 billion. The revenue comparison was affected by
heavy year-2000-related purchases that occurred in December 1999, the
company said.

David Mahoney, chief executive of subsidiary iMcKesson, told analysts that
the iMcKesson business is in the early stages of a turnaround, and that he was
pleased with the quarter. The full impact of its new contracts, however, won't
be seen until the next fiscal year, Mahoney said.

The unit posted a 2.4% rise in revenue, to $72.3 million from $70.6 million. It
had a $12.5 million operating loss, compared with a $4.1 million profit in the
year-ago quarter, both before special items.

-By Dinah Wisenberg Brin, Dow Jones Newswires; 215-656-8285;
dinah.brin@dowjones.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10